High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome

High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome

Background: CTLA-4 impedes the immune system’s antitumor response. There are two Food and Drug Administration-approved anti-CTLA-4 agents – ipilimumab and tremelimumab – both used together with anti-PD-1/PD-L1 agents. Objective: To assess the prognostic implications and immunologic correlates of hig...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Nithya Krishnamurthy, Daisuke Nishizaki, Scott M. Lippman, Hirotaka Miyashita, Mary K. Nesline, Sarabjot Pabla, Jeffrey M. Conroy, Paul DePietro, Shumei Kato, Razelle Kurzrock
Định dạng: Bài viết
Ngôn ngữ:English
Được phát hành: SAGE Publishing 2024-01-01
Loạt:Therapeutic Advances in Medical Oncology
Truy cập trực tuyến:https://doi.org/10.1177/17588359231220510

Internet

https://doi.org/10.1177/17588359231220510

Những quyển sách tương tự